Thermo Fisher Scientific (TMO)
(Delayed Data from NYSE)
$598.03 USD
-17.66 (-2.87%)
Updated Aug 5, 2024 04:00 PM ET
After-Market: $598.05 +0.02 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$598.03 USD
-17.66 (-2.87%)
Updated Aug 5, 2024 04:00 PM ET
After-Market: $598.05 +0.02 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
The Zacks Analyst Blog Highlights: AMETEK, Thermo Fisher Scientific, IQVIA, Lowe's Companies and Alexion Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AMETEK, Thermo Fisher Scientific, IQVIA, Lowe's Companies and Alexion Pharmaceuticals
5 Most-Loved S&P 500 Stocks on Wall Street
by Sweta Killa
Given the bullishness and record-high market, we have screened for five S&P 500 stocks that are most loved by the brokerage firms.
Penumbra's (PEN) Q3 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Penumbra (PEN) witnessed strong growth across all geographies and product lines in Q3.
Dentsply (XRAY) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Dentsply (XRAY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
DexCom (DXCM) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Nevro (NVRO) Q3 Loss Narrower Than Expected, Revenues Up Y/Y
by Zacks Equity Research
Nevro (NVRO) launches the Senza Omnia SCS System commercially in the United States in Q3.
DexCom (DXCM) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
DexCom's (DXCM) Q3 earnings benefit from higher revenues, solid performing Sensor and Transmitter segments and strong 2019 outlook. However, contraction in gross margin remains a woe.
Glaukos (GKOS) Q3 Loss Narrower Than Expected, '19 View Up
by Zacks Equity Research
Glaukos' (GKOS) Q3 revenues surge year over year. Also, the company raises 2019 revenue guidance.
LHC Group (LHCG) Q3 Earnings Surpass Estimates, Revenues Lag
by Zacks Equity Research
LHC Group (LHCG) third-quarter results benefit from home health and hospice admissions and higher revenues.
National Vision's (EYE) Q3 Earnings Top Estimates, View Raised
by Zacks Equity Research
National Vision's (EYE) third-quarter performance reflects strong growth in core business segments.
Option Care Health (BIOS) Q3 Earnings Meet, Revenues Top
by Zacks Equity Research
Albeit Option Care Health (BIOS) is yet to reap material benefits from its merger-related synergies, the reporting of a positive gross margin in third-quarter results is encouraging for investors.
DENTSPLY SIRONA (XRAY) Beats on Q3 Earnings, Ups '19 View
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) gains from solid segmental contributions in Q3.
Globus Medical (GMED) Q3 Earnings Meet Mark, Revenue View Up
by Zacks Equity Research
Globus Medical (GMED) reports robust top-line numbers for the third quarter on segmental strength.
Hologic's (HOLX) Q4 Earnings Meet, Revenues Top Estimates
by Zacks Equity Research
Hologic (HOLX) exhibits robust fourth-quarter growth fueled by strong segmental performance.
Cardinal Health (CAH) Q1 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Cardinal Health (CAH) Q1 results benefit revenue growth and strong segmental performance. However, contraction in gross margin remains a concern.
AmerisourceBergen (ABC) Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
AmerisourceBergen's (ABC) Q4 earnings benefit from higher revenues, segmental growth and strong fiscal 2020 outlook.
Insulet (PODD) Beats on Q3 Earnings, Ups '19 Revenue View
by Zacks Equity Research
Insulet's (PODD) year-over-year improvement in Q3 revenues on the solid uptake of Omnipod system both in the United States and across international markets looks promising.
OPKO Health (OPK) Q3 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
OPKO Health (OPK) third-quarter results benefit from higher Product revenues and RAYALDEE prescription growth.
CVS Health (CVS) Beats on Q3 Earnings, Raises '19 EPS Guidance
by Zacks Equity Research
CVS Health's (CVS) strong year-over-year growth in the top line is aided by a robust performance at the Pharmacy Services segment.
Phibro's (PAHC) Q1 Earnings & Revenues Fall Y/Y, Margins Down
by Zacks Equity Research
Phibro (PAHC) exhibits a dismal first-quarter performance on a decline in revenues at core business segments.
HMS Holdings (HMSY) Q3 Earnings Top Estimates, Revenues Miss
by Zacks Equity Research
HMS Holdings' (HMSY) Q3 earnings benefit from higher revenues at Analytical Services unit and strong 2019 outlook.
Avanos (AVNS) Earnings and Revenues Miss Estimates in Q3
by Zacks Equity Research
Avanos (AVNS) third-quarter results benefit from higher revenues and strong segmental performance.
Zacks.com featured highlights include: SYNNEX, Thermo Fisher Scientific, Allstate, Intel and Target
by Zacks Equity Research
Zacks.com featured highlights include: SYNNEX, Thermo Fisher Scientific, Allstate, Intel and Target
Inogen's (INGN) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Softness in domestic and international business-to-business revenues impact Inogen's (INGN) Q3 results.
DaVita (DVA) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
DaVita (DVA) raises guidance for 2019 following impressive Q3 results.